Device Trial Radar · NCT04129034
Safety and Initial Feasibility of Using the Neurolyser XR Device for the Treatment of Axial Chronic Low Back Pain
Last checked: Nov 20, 2026Latest source record: Dec 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
30
Actual
Start
Sep 24, 2019
Primary completion
Oct 26, 2022
Study completion Mar 26, 2023
Sponsor
- Lead sponsor
- FUSMobile Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 16, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 55 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Single arm pilot study to evaluate the safety and initial feasibility of the Neurolyser XR, a high intensity focused ultrasound device, for non-invasive treatment of axial chronic low back pain
Conditions
- Facet Syndrome of Lumbar Spine
Interventions
Neurolyser XRDevice
Non-Invasive Thermal Ablation of the Medial Branch Nerves
Primary outcomes
What the sponsor says the trial is designed to measure.
- NRSTime frame: Time Frame: Base line, 2 days 1, 2 & 4 weeks, 3 & 6 months after procedure
- Procedure and Device Safety at six months as measured by measured by the incidence and severity of treatment related adverse eventsTime frame: Time Frame: 6 months after procedure
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Kinetix Medicine
Vancouver, British Columbia, Canada
Precision Sport & Spine
Oakville, Ontario, Canada
Silver Medical Group
Toronto, Ontario, Canada
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.